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Epigenetic transcriptional regulation plays an important role in the life cycle of human papillomaviruses (HPVs) and the carcinogenic
progression of anogenital HPV associated lesions. We performed a study designed to assess the methylation status of the HPV-18 genome,
specifically of the late L1 gene, the adjacent long control region (LCR), and part of the E6 oncogene in cervical specimens with a range of
pathological diagnoses. In asymptomatic infections and infections with precancerous (precursor) lesions, HPV-18 DNAwas mostly unmethylated,
with the exception of four samples where hypermethylation of L1 was detected. In contrast, L1 sequences were strongly methylated in all cervical
carcinomas, while the LCR and E6 remained unmethylated. HeLa cells, derived from a cervical adenocarcinoma, contain chromosomally integrated
HPV-18 genomes. We found that L1 is hypermethylated in these cells, while the LCR and E6 are unmethylated. Treatment of HeLa cells with the
methylation inhibitor 5-Aza-2′-deoxycytidine (5-Aza-CdR) led to the expected reduction of L1 methylation. After removal of 5-Aza-CdR, L1
methylation resumed and exceeded pretreatment levels. Unexpectedly, the LCR and E6 also became methylated under these conditions, albeit at
lower levels than L1. We hypothesize that L1 is preferentially methylated after integration of the HPV genome into the cellular DNA, possibly since
linearization prohibits its normal transcription, while the enhancer and promoter may be protected from methylation by transcription factors. Since
our data suggest that HPV-18 L1 methylation can only be detected in carcinomas, except in some few precancerous lesions and asymptomatic
infections, L1 methylation may constitute a powerful molecular marker for detecting this important step of neoplastic progression.
© 2006 Elsevier Inc. All rights reserved.Keywords: Papillomavirus; Cervical carcinoma; Epigenetic; Transcription regulationIntroduction
Human papillomaviruses (HPV) are implicated as causative
agents in the etiology of cervical cancer (International Agency
for Research on Cancer, 1995). Eighteen HPV types are
associated with nearly 100% of all cervical carcinomas, and
among these types, HPV-16 and HPV-18 account for approx-
imately two thirds of these malignant lesions worldwide
(Munoz et al., 2003). HPV-18 has been associated with more⁎ Corresponding author. Fax: +1 949 824 8551.
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doi:10.1016/j.virol.2005.12.033aggressive forms of cervical intraepithelial neoplasia (Schwartz
et al., 2001; Burk et al., 2003) and has a higher prevalence than
HPV-16 in adenocarcinomas (Andersson et al., 2001). In vitro,
the oncoproteins of HPV-16 and -18 have similar molecular
properties by binding the p53 and pRB tumor suppressor
proteins and interfering with their function (Dyson et al., 1989,
Werness et al., 1990). However, HPV-18 has been found to have
an increased potential for the immortalization of epithelial cells
(Schlegel et al., 1988), possibly due to the higher transcriptional
activity of its enhancer-promoter system (Villa and Schlegel,
1991; Romanczuk et al., 1991). In view of these findings and
the taxonomically remote relationship of HPV-16 and -18 (de
Villiers et al., 2004), our research pertaining to gene expression
176 T. Turan et al. / Virology 349 (2006) 175–183has aimed to investigate consistencies between these two
viruses in addition to type-specific molecular and pathological
distinctions.
For many years, investigations of HPV gene expression have
concentrated on the identification of sequence-specific tran-
scription factors (reviewed in Bernard, 2002). More recently, it
has become clear that epigenetic mechanisms, which influence
chromatin conformations that favor or repress gene expression,
play a major role in modulating HPV transcription (Stünkel and
Bernard, 1999; Zhao et al., 1999). One of several mechanisms
that affect chromatin conformation is the methylation of DNA,
specifically at cytidine-guanidine (CpG) dinucleotides. Meth-
ylated CpG dinucleotides (meCpGs) bind repressors such as
MeCP2, which alter the conformation of nucleosomes through
their interaction with histone deactylases in a manner
unfavorable to transcription (reviewed in Bird, 1992; Goll and
Bestor, 2005). Methylation of the genomes of HPV-1 and the
cottontail rabbit PV was observed more than 20 years ago
(Burnett and Sleeman, 1984; Sugawara et al., 1983; Wettstein
and Stevens, 1983). It has also been reported that, as would be
expected, in vitro methylated HPV-16 genomes are transcrip-
tionally repressed after transfection into cell culture (Rosl et al.,
1993). However, more recently, it was shown that methylation
of the DNA of HPV-16 and -18 takes place regularly in vivo in
cervical cells, in patients in situ in addition to cell cultures.
Present evidence suggests that the genomes of both viruses can
become methylated but apparently in different patterns and in
somewhat different pathological contexts (Badal et al., 2003,
2004; Kim et al., 2003; Van Tine et al., 2004; Kalantari et al.,
2004; Wiley et al., 2005). It raises questions of where and how
HPV genomes are recognized by the cellular DNA methylation
machinery and about the role of this mechanism during the HPV
life cycle and HPV-dependent carcinogenesis.
We previously reported that 10–20% of the CpGs of the long
control region (LCR) of HPV-16 DNA are found methylated in
asymptomatic infection. Methylation decreases strongly in
precursor lesions, while remethylation occurs in high-grade
lesions and carcinomas. It exceeds 50% in the case of some
CpG dinucleotides within the L1 gene (Kalantari et al., 2004;
Wiley et al., 2005). The transition between hypermethylation in
asymptomatic infection and hypomethylation in low-grade
lesions correlates with evidence that W12 cell cultures with
episomal HPV-16 genomes maintain the viral DNA in a
hypermethylated state in undifferentiated cells with hypomethy-
lation occurring upon differentiation (Kim et al., 2003). This
finding supports the hypothesis that HPV-16 can be transcrip-
tionally repressed upon infection. In order to initiate the
transforming process, it has to become demethylated as has
been found in clinical samples (Kalantari et al., 2004) and cell
cultures (Kim et al., 2003). In carcinomas, HPV-16 DNA is
normally not found in the episomally replicating form but rather
is integrated into the cellular DNA (Schwarz et al., 1985; Daniel
et al., 1995). It is probably not surprising that this correlates
with increased methylation (Kalantari et al., 2004; Wiley et al.,
2005), since DNA integrating into cellular chromosomes is a
preferential target for methylation and transcriptional inactiva-
tion (Doerfler et al., 2001) per se. Therefore, there may not be aspecific recognition of HPV-16 DNA in this scenario. The
possibility of a specific recognition mechanism has been
proposed, however, leading to the selective activation of a
few HPV-16 genomes in each cell for maintenance of the
neoplastic state (Van Tine et al., 2004).
The project reported here aimed to refine our knowledge of
the role of methylation in HPV-18. Our findings are based on a
strategy in which we purified DNA from clinical samples and
cultured cells, bisulfite treated and PCR amplified this DNA,
and cloned the product into an E. coli vector for analysis of
individual HPV-18 segments. Our investigations of HPV-16 had
pointed to the need for this refined approach, as we had learnt
that individual samples and even cell lines contain mixtures of
differentially methylated HPV-16 genomes (Kalantari et al.,
2004; Wiley et al., 2005). Therefore, analyses based entirely on
restriction digestions or direct bisulfite sequencing (Badal et al.,
2004) do not lead to robust analyses of this phenomenon. The
findings of this study taken together with our previous
publications suggest that significant differences exist in the
epigenetic regulation of HPV-16 and -18 and that L1
methylation could prove to be a powerful biomarker by which
to study tumor progression.
Results
Hypomethylation of the HPV-18 L1 gene and the LCR in
asymptomatic patients
The objective of our study was to establish the diversity of
methylation patterns in the 3′ part of the L1 gene and
throughout the LCR into the 5′ part of the E6 gene of HPV-18
covering a segment of about 1.2 kb with 31 CpG dinucleotides
serving as potential methylation targets. This was done after
bisulfite treatment of sample DNA, which converts cytosine
residues into uracils, while not affecting methyl-cytosine
residues. PCR converts the uracils into thymine and the
methyl-cytosines into cytosine residues, and DNA sequencing
of the PCR product allows for the determination of the
methylation pattern before treatment. We analyzed five clones
from each clinical sample in order to observe any potential
heterogeneity between different HPV-18 genomes within
individual samples as detected in our analyses of HPV-16
(Kalantari et al., 2004). Since bisulfite treatment precludes the
amplification of large DNA segments, we split the 1.2-kb
target into three amplicons of approximately equal size, the
first correlating with the 3′ part of the L1 gene, the second with
the enhancer, the third with the promoter and 5′ end of the E6
gene.
Fig. 1A shows the results obtained with eleven DNA extracts
from cervical smears diagnosed as pathologically normal. Three
and eight of these samples came from Mexican and Brazilian
patients, respectively. It was evident that these samples were
only very lightly methylated, with meCpGs observed in only 64
of 1671 positions (3.8%). Altogether, 36 out of 55 HPV-18
genomes were completely unmethylated implying they were
transcriptionally unaffected. Most of the methylation was
evident in only three samples, which accounted for 49 of the
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meCpGs in the L1 gene, and only a single meCpG in the LCR.
The methylation rate was 7.5% (44 meCpGs among 595 CpGs)
in L1, 2.8% (14 meCpGs among 492 CpGs) in the enhancer
segment, and 1% (6 meCpGs among 594 CpGs) in the promoter
segments. This sample and the second one in Fig. 1A with
substantial L1 methylation came from the Brazilian cohort,
which otherwise contained hypo- and unmethylated samples.
We obtained very similar data for 13 other DNA samples from
asymptomatic patients of the same two cohorts, although we
could not establish complete data sets because of a shortage of
DNA (data not shown). We conclude that methylation
is generally very light in asymptomatic HPV-18 infections,
with occasional sample-specific increases, preferentially occur-
ring in L1.
Hypomethylation of the HPV-18 L1 gene and the LCR in
precancerous (precursor) lesions
Fig. 1B shows the results obtained with twelve DNA extracts
of cervical smears diagnosed with cytological abnormalities.
Specifically, five samples were graded as mild dyskaryosis,
which equates to a low-grade abnormality/lesion (the uppermost
five data groups in Fig. 1B), and three samples showed
“borderline nuclear changes” (equating most closely to ASCUS,
i.e., atypical squamous cells of undetermined significance) (the
sixth to eighth data group in Fig. 1B). Four samples were graded
as severe dyskaryosis, which equates to a high-grade abnor-
mality/lesion. All of these samples came from patients from
Edinburgh. Similar to the findings with pathologically normal
samples, HPV-18 was only very lightly methylated in the
majority of these precursors. meCpGs were observed in only 77
of a total of 1849 positions (4.0%). Altogether, 33 out of 60
HPV-18 genomes were completely unmethylated and therefore
were likely to be unaffected transcriptionally. Most of the
methylation was evident in only two samples, which accounted
for 57 of the 77 meCpGs. The HPV-18 genomes in these two
samples (the ninth and the eleventh sample in Fig. 1B) had most
of the methylation in the L1 gene. It was also interesting to note
that the two, heavily methylated genomes, had been extracted
from samples that had high-grade abnormalities. Ordered by
genomic region, the methylation rate was 8.9% (59 meCpGs
among 660 CpGs) in L1, 1.5% (8 meCpGs among 529 CpGs) in
the enhancer segment, and 1.5% (10 meCpGs among 660
CpGs) in the promoter segments. We conclude that methylation
is generally very light in HPV-18 containing low-grade
precursor lesions, with a potential for intense methylation,
however, in high-grade lesions.
Hypermethylation of the HPV-18 L1 gene in carcinomas
Fig. 1C shows the results obtained with 14 DNA prepara-
tions from cervical squamous carcinomas. Thirteen of these
samples came from patients from Norway and one from a
patient in Mexico. Fig. 1C clearly depicts the high methylation
rate of the HPV-18 L1 gene in all of these samples in contrast to
the sporadic methylation in the LCR. Altogether, meCpGs wereobserved in 647 among a total of 2170 positions (29.8%). Only
four of the 70 HPV-18 genomes were completely unmethylated.
Ordered by genomic region, the methylation rate was 76.8%
(592 meCpGs among 770 CpGs) in L1, 2.7% (17 meCpGs
among 630 CpGs) in the enhancer segment, and 4.8% (37
meCpGs among 770 CpGs) in the promoter segments. We
conclude that there is a strong bias for methylation of L1 in
carcinomas. Figs. 2A to C represent the summary of the
methylation patterns observed in clinical samples in form of bar
diagrams.
Preferential methylation of the HPV-18 L1 gene in HeLa cells
In order to evaluate the stability of the methylated/
unmethylated state across the L1-LCR junction, we decided
to study methylation changes in an HPV-18 containing cancer
cell line in the presence and absence of a methylation inhibitor.
We have previously reported that in HeLa cells, which contain
about 50 chromosomally integrated HPV-18 copies, the L1
gene is methylated, while the LCR is devoid of meCpGs (Badal
et al., 2004). These data were based on two fairly crude
techniques, namely digestion with the restriction enzyme
McrBC and direct sequencing of PCR amplicons generated
after bisulfite modification. Here, we aimed to establish a
precise pattern of methylation across the same 31 CpG
dinucleotides between the 3′ part of the L1 gene and the 5′
part of E6 that were analyzed in clinical samples. Fig. 3A shows
an analysis of three amplicons covering this genomic region, as
described above. In the L1 gene, we found 100 meCpGs among
264 CpG dinucleotides, which cumulatively corresponds to an
overall methylation rate of 38%. There were only five of 216
CpGs (1.9%) methylated in the enhancer segment and none in
the promoter segment.
We considered it unlikely that the methylation discontinuity
observed between the 3′ end of L1 and the 5′ part of the LCR
observed in HeLa cells and clinical samples could be an artifact
occurring during the generation of the two separate amplicons.
However, in order to validate this assumption, we created
amplicons across this boundary that included CpG residues
from the L1 gene as well as some from the 5′ side of the LCR
(amplicons Msp7F and R, see Materials and methods section).
All amplicons derived from samples with L1 methylation
generated by this strategy had the same discontinuity of the
methylated state across the positions 7317 or 7122, respectively
(data not shown), as evident from Fig. 2A. We conclude that the
specific methylation patterns that we observed in this genomic
region are not artifacts of primer design or primer position.
The effect of 5-Aza-CdR treatment and withdrawal on HPV-18
L1 methylation in HeLa cells
5-Aza-CdR is an inhibitor of the maintenance DNA
methyltransferase DNMT1, and can be used in cell culture to
interfere with CpG methylation and to assess its reestablishment
after removal of the drug. Here, we attempted to monitor the
effects that this drug had on the methylation of HPV-18 L1
sequences, specifically, to observe which genomic regions are
178 T. Turan et al. / Virology 349 (2006) 175–183targeted after subsequent culture of the HeLa cells in the
absence of the drug.
Fig. 3B shows that HPV-18 L1 sequences analyzed after
growth of HeLa cells in the presence of 5-Aza-CdR exhibited amoderate reduction in the amount of methylated L1 sequences
to 28% (75 meCpGs among 264 CpG residues). There were no
methylated CpGs in the enhancer and promoter amplicons.
After subsequent growth of the 5-Aza-CdR treated cells for 20
days in the absence of this methylation inhibitor, L1
methylation resumed and reached a level of 61% (162 meCpGs
among 264 CpG residues), significantly exceeding the
pretreatment level of 38% (Fig. 3C). While the enhancer and
promoter had been nearly completely unmethylated in the
absence of 5-Aza-CdR, treatment with this drug and its
subsequent removal led to an unexpected and surprising de
novo methylation of 38 out of 216 CpG residues (17.6%) of the
enhancer segment and 122 of 264 CpGs (46%) of the promoter
segment, indicating a lack of complete protection from
methylation of the LCR, but a maintenance of limited protection
of the segment that binds important enhancer factors like AP-1.
Fig. 4 summarizes these observations.
Discussion
Research outside the papillomavirus field has led to the
theory of an “epigenetic conversation network” involving
histone acetylation, histone deacetylation, cytosine methylation,
and histone methylation. These reactions covalently modify
nucleosomes and DNA and lead either to a transcriptionally
competent or silenced chromatin (Fuks, 2005). Some of these
regulatory mechanisms are well established in papilloma-
viruses: the LCRs of HPV-6, -11, -16, and -18 genomes each
contain a silencer recognized by the transcriptional repressors
CDP and YY1, which interact with histone deacetylases
(HDACs) and thereby repress the enhancer and E6 promoter
(Bauknecht et al., 1992; O'Connor et al., 1996, 2000; Pattison et
al., 1997; Zhao et al., 1999; Ai et al., 2000). It is likely that this
process links HPV transcription with epithelial differentiation
(Stünkel and Bernard, 1999; Ai et al., 2000). CDP and YY1 also
bind histone methyltransferases, leading to methylated histones,
association with DNA methyltransferases, and methylated
cytosines (Fuks, 2005). The resulting meCpG residues bind
factors such as MeCP2, which repress transcription through
interactions with HDACs. While histone methylation has notFig. 1. CpG methylation of the L1 gene, the enhancer, promoter, and the 5′ part
of the E6 gene of HPV-18 in asymptomatic infections, precancerous lesions and
carcinomas of the cervix. Methylated CpGs are shown as black rectangles,
unmethylated CpGs as white rectangles. Each vertical bar of rectangles
identifies a genomic position, which is specified by number at the top of the
figure. Each horizontal bar of rectangles identifies an E. coli clone of HPV-18
obtained after bisulfite modification and PCR amplification of the sample DNA.
Each sample is represented by five E. coli clones, as grouped in the figure.
Occasional omissions, for example in the first vertical bar, indicate poor DNA
sequence quality. The gaps between the L1, enhancer, and promoter groups of
CpGs separate three different amplicons, since it is not possible to obtain 1.2-kb
amplicons with bisulfite modified DNA due to degradation. Therefore, each
horizontal bar is derived from three differentHPV-18 genomes as separated by the
gaps. (A) DNA from asymptomatic cervical infections. (B) DNA from
precancerous lesions. For pathological explanations, see the Results section. (C)
DNAfromcervical carcinomas.Thediscontinuityofmethylation in someselected
carcinomas across the positions 7122 and 7317 was confirmed by contiguous
amplicons as explained the Materials and methods and Results sections.
Fig. 2. CpG methylation of the L1 gene, the enhancer, promoter, and the 5′ part
of the E6 gene of HPV-18 in asymptomatic infections, precancerous lesions and
carcinomas of the cervix. Representation of the data of Fig. 1 in form of a bar
diagram.
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the decreasing concentrations of CDP, YY1 (Pattison et al.,
1997; Ai et al., 2000), and HPV-16 DNA methylation (Kim et
al., 2003; Kalantari et al., 2004) during epithelial differentiation
suggests an involvement of this mechanistic network in the
repression of HPV-16 in undifferentiated epithelial cells in vitro
and in asymptomatic infections in situ. This model accom-
modates the data available for HPV-16 (Badal et al., 2003; Kim
et al., 2003; Kalantari et al., 2004), which indicate that
methylation targets HPV-16 genomes in basal layers of
squamous epithelia, and a balance between methylation and
demethylation appears to influence the viral life cycle and
decisions between latent and progressing infections.
In contrast, the findings that we report here do not provide
evidence for a similar scenario in HPV-18 as we detected only
very low methylation, and often none, in the HPV-18 LCR in
asymptomatic infections. The small sample size that was
available to us precludes a final conclusion that HPV-16 andHPV-18 really do respond differentially to the cellular
methylation machinery (potentially in line with their fairly
remote relationship), or whether divergence may originate from
different cellular contexts, as HPV-18 may preferentially target
columnar rather than squamous epithelia. Nevertheless, these
discrepancies are surprising in view of the extensive similarities
in the transcription biology of HPV-16 and -18, which bind the
same transcription activators and repressors and show a similar
chromatin structure with specifically positioned nucleosomes
(Stünkel and Bernard, 1999).
In carcinomas, however, HPV-16 and -18 show similarly a
preferential methylation of the L1 gene, and the particularly
intense methylation of the HPV-18 L1 gene in all carcinomas,
exceeding 80% at some CpG positions, is the most intriguing
finding of this study. In HPV-16 associated carcinomas the
methylation frequency of three CpGs overlapping with L1 was
also pronounced but only slightly exceeded 50%. We had
reported in a previous paper that the HPV-18 L1 gene is
preferentially methylated (Badal et al., 2004). This latter study
included a few cell lines and clinical samples, and was based on
restriction digestion and direct sequencing, two techniques with
limited resolution. In that past paper, we had reported that
methylation was often absent from all parts of the viral genome
except L1 (Badal et al., 2004). In the present study, we have
described refined HPV-18 methylation maps, which has led to
the observation that preferential methylation of L1 extends
through the 3′ part of the L1 gene precisely to position 7122,
which is the last CpG within L1, ten nucleotides upstream of the
termination codon of this gene. Occasionally methylation
extends to position 7317, 185 bp within the LCR. This region
is normally referred to as 5′ LCR and does not include
sequences relevant for enhancer function, while the enhancer
overlaps with the CpG at position 7460 (part of an E2 binding
site) and all CpGs 3′ of this position. An explanation for the
precise methylation of L1 may be the fact that this gene is
unlikely to be transcribed after recombination in the cancerous
state, where L1 is located upstream of the viral transcription
regulatory elements. However, the LCR is also not transcribed,
and one may have to postulate that its hypomethylated state is
maintained through interaction with transcription factors.
The striking difference between intense L1 methylation in all
carcinomas and lack of L1 methylation in most asymptomatic
smears and low-grade precursor lesions suggests that one
should explore whether L1 methylation may be a useful
biomarker to study carcinogenic progression. It is noteworthy
that the only two precursor lesions with intense L1 methylation
had been pathologically diagnosed as high-grade lesions, and it
is conceivable that they contained an HPV-18 genome in a
molecular state indicative of cancer. Our observation of two
smears with L1 methylation, which had been pathologically
diagnosed as normal, may point to the power of this approach.
Intense methylation of HPV-18 L1 may identify cell popula-
tions with integrated HPV-18 genomes and therefore with a
molecular predisposition toward high-grade lesions or carcino-
mas and may highlight pathological misdiagnoses. However,
we are aware of the alternative that the early-late switch of
papillomaviruses may be accompanied by changes of the
Fig. 4. CpG methylation of the L1 gene, the enhancer, promoter, and the 5′ part
of the E6 gene of HPV-18 in HeLa cells and changes during and after treatment
with 5-Aza-CdR. Representation of the data of Fig. 2 in form of a bar diagram to
visualize the methylation discontinuity across the genomic position 7122 (at the
3′ end of L1) and 7317 (in the 5′ part of the LCR), and de novo hypermethylation
of the enhancer and promoter after withdrawal of the methylation inhibitor.
Fig. 3. CpG methylation of the L1 gene, the enhancer, promoter, and the 5′ part
of the E6 gene of HPV-18 in HeLa cells (A) and changes during (B) and after (C)
treatment with 5-Aza-CdR. Methylated CpGs are shown as black rectangles,
unmethylated CpGs as white rectangles. Each vertical bar of rectangles
identifies a genomic position, which is specified by number at the top of the
figure. Each horizontal bar of rectangles identifies an E. coli clone of HPV-18
obtained after bisulfite modification and PCR amplification of the sample DNA.
The gaps between the L1, enhancer, and promoter groups of CpGs separate three
different amplicons, since it is not possible to obtain 1.2-kb amplicons with
bisulfite modified DNA due to degradation. Therefore, each horizontal bar is
derived from three different HPV-18 genomes as separated by the gaps. The
discontinuity of methylation across the positions 7122 and 7317 was confirmed
by contiguous amplicons as explained the Materials and methods and Results
sections. The number of clones studied in part of Fig. 2B was reduced for
economic and not for scientific reasons, as there was no good reason to study the
influence of a methylation inhibitor on the demethylated DNA segment.
180 T. Turan et al. / Virology 349 (2006) 175–183methylation status of late genes, and it is possible that our
analysis may differentiate between HPV-18 infections with
expressed or repressed late genes. We are in the process of
improving the technical power of the study of HPV-18
methylation by procedures that selectively detected methylated
CpGs, such as meCpG-specific amplification primers and
methylation-specific molecular beacons included in real-time
PCR experiments.
We observed partial demethylation of HPV-18 L1 in HeLa
cells under the influence of 5-Aza-CdR, as expected from
similar studies of methylated CpGs in cellular chromosomes
(Velicescu et al., 2002). It is striking that a re-methylation
pattern at the border of L1 and the LCR flanking the position
7317 becomes reestablished after discontinuation of 5-Aza-
CdR treatment. Methylation exceeded 60% at position 7122
and at all CpGs to the 5′ side and was present at 3–20% levels
at the eight CpGs to the 3′ side, overlapping with the enhancer.This observation strengthens the case for L1 as a unique
methylation target, as it is apparently selectively recognized
subsequent to 5-Aza-CdR treatment. We do not have an
explanation for the methylation of LCR segments, particularly
at the promoter of HPV-18, under these conditions, which are
spared from methylation during the regular culture of HeLa
cells. It has been proposed, however, that remethylation after
removal of CpGs may show cell type-specific idiosyncrasies
due to differential expression of both the de novo methylase
DNMT3a and the maintenance methylase DNMT1 (Velicescu
et al., 2002). It is evident from this and previous studies that
the concept of “epigenetic conversation” applies to papilloma-
virus gene regulation, and that continuing studies of HPV
genome methylation will likely have considerable impact both
181T. Turan et al. / Virology 349 (2006) 175–183to the understanding of the HPV life cycle as well as to
molecular insight into and diagnosis of cancer progression
events.
Materials and methods
Clinical specimens
DNA samples extracted from cervical carcinomas were
obtained from an archival collection of tumors maintained at the
Department of Pathology, Norwegian Radium Hospital, Oslo,
Norway, and from a specimen obtained during a published
study on the genomic diversity of HPVs in Monterrey, Mexico
(Calleja-Macias et al., 2004). All of these samples had been
diagnosed as squamous carcinomas and none as adenocarcino-
mas, which are frequently associated with HPV-18. DNA
extracted from the residual material of normal and abnormal
cervical smear preparations was obtained from archival
collections established as a result of previous epidemiological
studies at the Ludwig Institute for Cancer Research in Sao
Paulo, Brazil (L.L.V.), at the Department of Pathology, National
Hospital, Oslo, Norway (B.H.), the Royal Infirmary of
Edinburgh, Edinburgh, Scotland (H.A.C. and K.C.), and from
a collection of samples (Fajardo and Barrera-Saldaña, unpub-
lished) that reconfirmed a recent investigation from Monterrey,
Mexico (Calleja-Macias et al., 2004). No patient was sampled
for the purpose of the specific research described here.
Unfortunately, the fact that only very few laboratories in the
world have large collections of HPV-18 positive samples (due to
the relatively low prevalence of this virus compared to HPV-16)
led to a bias of geographic overrepresentation in some
pathological categories. Thirteen out of fourteen cancer samples
came from Oslo, and all DNA extracted from abnormal smears
(consistent with evidence of precursor lesions) came from
Edinburgh. We do not believe, however, that these geographic
biases influenced the study outcome, as we found no correlation
between methylation state and geographic origin in previously
published research on HPV-16 (Kalantari et al., 2004).
Cell culture and DNA preparations
HeLa cells have been derived from a cervical adenocarci-
noma and have been well studied to contain approximately 50
HPV-18 copies in several chromosomal loci (Ambros and
Karlic, 1987; Mincheva et al., 1987; Popescu et al., 1987; Lazo
et al., 1989). We used a strain of HeLa cells that has been
maintained in our laboratory for many years. Although strains
of HeLa cells have been cultured separately for many decades,
our recent comparison of several HeLa strains did not point to
major differences in the composition and epigenetic status of
their endogenous HPV-18 genomes (Badal et al., 2004). HeLa
cells were grown in standard DME medium with 10% fetal
bovine serum. The methylation inhibitor 5-Aza-2′-deoxycyti-
dine (5-Aza-CdR) was used at a concentration of 1 μM for 3
days. All DNA preparations from HeLa cells and clinical
samples were purified with Qiagen genomic tips following
protocols suggested by the supplier.Bisulfite modification
For bisulfite treatment, 50–1000 ng of sample DNA
supplemented with 1 μg of salmon sperm DNA in a total
volume of 18 μl in water was denatured with 2 μl of 3 M
NaOH and incubated at 37 °C. After denaturation, 278 μl of
4.8M sodium bisulfite and 2 μl of 100 mM hydroquinone
were added with the mixture being incubated in a thermal
cycler for 20 cycles of 55 °C for 15 min and 95 °C for 30 s.
The modified DNA was desalted with the QIAquick PCR
purification protocol and desulfonated thereafter by adding 5.5
μl of 3M NaOH and 5 μg glycogen prior to 15-min
incubation at 37 °C. The DNA was precipitated with 5.6 μl
of 3 M sodium acetate and 150 μl of 100% ethanol, followed
by centrifugation. The pellet was washed with 70% ethanol
and dissolved in 30–50 μl TE buffer (10 mM Tris–HCl pH 8,
1 mM EDTA).
Polymerase chain reactions, primers, T/A cloning and DNA
sequencing
Since bisulfite-treated DNA is partially degraded, large
amplicons cannot be generated, so we divided the HPV-18
segment that we wanted to study into three amplicons between
the genomic position 6845–7186, 7282–7747, and 7753–186.
The sequences of the primers were designed according to the
genomic sequence of HPV-18 (Myers et al., 1994) assuming
conversion of all cytosine residues into uracils. The genomic
segment 6845–7186 encompassed the 3′ part of the L1 gene
and was amplified with the primers Msp6Fa, AATTATTA-
GTTTGGTGGATATATAT (position 6845–6869) and Msp6R,
AAAACATACAAACACAACAATAAATA (position 7186–
7161). The genomic segment 7282–7747 with the 5′ part of
the LCR and its center, including the viral enhancer, was
amplified with the primers Msp10F, TAAAATATGT-
TTTGTGGTTTTGTG (position 7282–7293) and Msp10R,
ATAATTATACAAACCAAATATACAATT (position 7747–
7721). The genomic segment 7743–186 with the viral
replication origin, the E6 promoter and the 5′ part of the E6
gene was amplified with the primers Msp8F TGTTTAA-
TATTTTGTTTATTTTTAATATG (position 7753–7781) and
Msp8R, TATCTTACAATAAAATATTCAATTCC (position
186–161). In selected samples, we amplified a fourth segment
that spanned the border between the 6845–7186 and 7282–7747
amplicons, using the primers Msp7F, AGATTTAGATTAA-
TATTTTTTTGGA (position 6986–7010) and Msp7R, AAAT-
TAAAATTTACAATAATACCAAC (position 7537–7512).
PCR was carried out in a 25 μl volume containing 0.2 mM of
each of the four dNTPs, 10 pmol of each primer, 2 mM MgCl2
and 1 U of Ampli Taq Gold (Perkin-Elmer). The PCR
conditions were 94 °C for 1 min, followed by 40 cycles of
94 °C for 10 s, 54 °C for 30 s, and 68 °C for 1 min with a final
extension at 68 °C for 7 min. The presence of PCR products was
verified by agarose gel electrophoresis, and confirmed ampli-
cons were cloned with the TOPO TA cloning kit for sequencing
(Invitrogen). Cloned DNAs were sequenced by Big Dye
terminator v3.1 Cycle Sequencing (Applied Biosystems).
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